STOCK TITAN

Tenaya Therapeutics, Inc. - TNYA STOCK NEWS

Welcome to our dedicated page for Tenaya Therapeutics news (Ticker: TNYA), a resource for investors and traders seeking the latest updates and insights on Tenaya Therapeutics stock.

Tenaya Therapeutics, Inc. (NASDAQ: TNYA) is a clinical-stage biotechnology company dedicated to discovering, developing, and delivering potentially curative therapies that address the underlying causes of heart disease. Founded in 2016 and headquartered in South San Francisco, Tenaya Therapeutics leverages its integrated platforms in Gene Therapy, Cellular Regeneration, and Precision Medicine to advance a pipeline of novel therapeutic candidates targeting both rare genetic cardiovascular disorders and more prevalent heart conditions.

Tenaya's flagship programs include TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301, a small molecule HDAC6 inhibitor for heart failure with preserved ejection fraction (HFpEF). In late October 2023, the company announced the U.S. FDA clearance of its Investigational New Drug (IND) application for TN-401, initiating the RIDGE-1 Phase 1b clinical trial to evaluate its safety, tolerability, and efficacy.

Tenaya is a preclinical-stage company but has made significant strides. Its gene therapy TN-401 aims to treat ARVC by delivering a fully functional PKP2 gene to restore protein levels necessary for heart muscle function. The company also focuses on genetic mutations responsible for heart diseases, aiming to reverse or halt disease progression efficiently.

The company’s commitment to innovation extends to its robust pipeline and strategic collaborations, ensuring progress in addressing unmet needs in cardiac care. With a fully operational Genetic Medicines Manufacturing Center, Tenaya can produce clinical trial material at scale, highlighting its readiness to transition groundbreaking research into clinical applications.

For the latest updates, detailed financial results, and corporate announcements, visit their official website at www.tenayatherapeutics.com.

Rhea-AI Summary
Tenaya Therapeutics has received FDA clearance to begin clinical testing of TN-401, an investigational gene therapy product candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC). TN-401 aims to address the underlying cause of ARVC by delivering a fully functional PKP2 gene to restore normal PKP2 protein levels. The company plans to initiate the RIDGE-1 Phase 1b clinical trial to assess the safety, tolerability, and clinical efficacy of TN-401.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.67%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics announces the first patient has been dosed with TN-201 gene therapy for the treatment of MYBPC3-associated HCM in a Phase 1b clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
Rhea-AI Summary
Tenaya Therapeutics announces publication of preclinical research on cardiac cellular regeneration in rodent models of chronic cardiac ischemic injury
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics to present TN-301 and TN-201 data at medical conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
-
Rhea-AI Summary
Tenaya Therapeutics CEO to participate in Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
conferences
Rhea-AI Summary
Tenaya Therapeutics reports financial results for Q2 2023 with a cash and investments balance of $152 million, providing funding into the first half of 2025. The company anticipates dosing the first patient in the Phase 1b trial of TN-201 in Q3 2023. TN-301 Phase 1 clinical trial data accepted for presentation at HFSA 2023. IND application for TN-401 gene therapy expected in the second half of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
-
Rhea-AI Summary
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) to Present at 43rd Annual Canaccord Genuity Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Summary
Tenaya Therapeutics reports progress in clinical trials and expansion of advisory boards
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.65%
Tags

FAQ

What is the current stock price of Tenaya Therapeutics (TNYA)?

The current stock price of Tenaya Therapeutics (TNYA) is $1.67 as of December 20, 2024.

What is the market cap of Tenaya Therapeutics (TNYA)?

The market cap of Tenaya Therapeutics (TNYA) is approximately 124.4M.

What is Tenaya Therapeutics, Inc.?

Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing curative therapies for heart diseases, leveraging gene therapy, cellular regeneration, and precision medicine platforms.

What is TN-401?

TN-401 is an investigational gene therapy developed by Tenaya targeting arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. It aims to restore normal protein levels in heart cells.

When was Tenaya Therapeutics established?

Tenaya Therapeutics was founded in 2016.

What are the main therapeutic programs of Tenaya Therapeutics?

Tenaya's main programs include TN-201 for hypertrophic cardiomyopathy (HCM), TN-401 for arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301 for heart failure with preserved ejection fraction (HFpEF).

Where is Tenaya Therapeutics located?

Tenaya Therapeutics is headquartered in South San Francisco, California.

What recent milestones has Tenaya Therapeutics achieved?

Recent milestones include FDA clearance for the TN-401 IND application and the initiation of the RIDGE-1 Phase 1b clinical trial.

What is the goal of TN-301?

TN-301 is a small molecule HDAC6 inhibitor aiming to treat heart failure with preserved ejection fraction (HFpEF) by improving cardiac function and reducing inflammation and fibrosis.

How is Tenaya Therapeutics advancing its therapies?

Tenaya advances its therapies through integrated gene therapy, cellular regeneration, and precision medicine platforms, supported by proprietary manufacturing capabilities.

What is the significance of the RIDGE-1 Phase 1b clinical trial?

The RIDGE-1 Phase 1b clinical trial evaluates the safety, tolerability, and efficacy of a one-time intravenous infusion of TN-401 in patients with PKP2-associated ARVC.

How can I get more information about Tenaya Therapeutics?

For more information, you can visit the official website of Tenaya Therapeutics at www.tenayatherapeutics.com.

Tenaya Therapeutics, Inc.

Nasdaq:TNYA

TNYA Rankings

TNYA Stock Data

124.38M
77.83M
1.17%
73.79%
16.56%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO